Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation

Journal of the American College of Cardiology

Volumn 61, Issue 9, 2013, Pages 971-980

  Habib, Anwer ^a   Karmali, Vinit ^a   Polavarapu, Rohini ^a   Akahori, Hirokuni ^a   Nakano, Masataka ^b   Yazdani, Saami ^b   Otsuka, Fumiyuki ^b   Pachura, Kim ^a   Davis, Talina ^a   Narula, Jagat ^c   Kolodgie, Frank D ^b   Virmani, Renu ^b   Finn, Aloke V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CVPATH INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cell proliferation; drug eluting stents; endothelium; metformin; S6K

Indexed keywords

BROXURIDINE; CD31 ANTIGEN; CYCLIN D1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PLACEBO; RAPAMYCIN; S6 KINASE; SMALL INTERFERING RNA; ZOTAROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BARE METAL STENT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ELUTING STENT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; ILIAC ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; AORTA; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DRUG INTERACTIONS; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; ILIAC ARTERY; METFORMIN; MICROSCOPY, ELECTRON, SCANNING; RABBITS; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS;

EID: 84875429179     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.12.018     Document Type: Article

References (36)

1. R.L. Frye, P. August, M.M. Brooks A randomized trial of therapies for type 2 diabetes and coronary artery disease N Engl J Med 360 2009 2503 2515
2. J. Daemen, P. Wenaweser, K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
3. G.W. Stone, E. Kedhi, D.J. Kereiakes Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus Circulation 124 2011 893 900
4. A. Caixeta, M.B. Leon, A.J. Lansky 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents J Am Coll Cardiol 54 2009 894 902
5. T. Kimura, T. Morimoto, Y. Nakagawa Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry Circulation 125 2012 584 591
6. A.V. Finn, M. Joner, G. Nakazawa Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441
7. G. Guagliumi, V. Sirbu, G. Musumeci Examination of the in vivo mechanisms of late drug-eluting stent thrombosis findings from optical coherence tomography and intravascular ultrasound imaging J Am Cardiol Intv 5 2012 12 20
8. D.D. Sarbassov, S.M. Ali, D.M. Sabatini Growing roles for the mTOR pathway Curr Opin Cell Biol 17 2005 596 603
9. Y.W. Chen, M.L. Smith, M. Sheets Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression J Cardiovasc Pharmacol 49 2007 228 235
10. C. Espeillac, C. Mitchell, S. Celton-Morizur S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy J Clin Invest 121 2011 2821 2832
11. N. Hay, N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945
12. R. Zoncu, A. Efeyan, D.M. Sabatini mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol 12 2011 21 35
13. A.V. Finn, M. John, G. Nakazawa Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation Circ Res 105 2009 1003 1012
14. H. Sasaki, H. Asanuma, M. Fujita Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase Circulation 119 2009 2568 2577
15. G. Zhou, R. Myers, Y. Li Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 2001 1167 1174
16. D.M. Gwinn, D.B. Shackelford, D.F. Egan AMPK phosphorylation of raptor mediates a metabolic checkpoint Mol Cell 30 2008 214 226
17. M. Joner, G. Nakazawa, A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342
18. F. Vinals, J.C. Chambard, J. Pouyssegur p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation J Biol Chem 274 1999 26776 26782
19. D.C. Fingar, C.J. Richardson, A.R. Tee, L. Cheatham, C. Tsou, J. Blenis mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E Mol Cell Biology 24 2004 200 216
20. G.G. Graham, J. Punt, M. Arora Clinical pharmacokinetics of metformin Clin Pharmacokinet 50 2011 81 98
21. B. Cool, B. Zinker, W. Chiou Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome Cell Metab 3 2006 403 416
22. K.J. Peyton, X.M. Liu, Y. Yu, B. Yates, W. Durante Activation of AMP-activated protein kinase inhibits the proliferation of human endothelial cells J Pharmacol Exp Ther 342 2012 827 834
23. R.J. Dowling, I. Topisirovic, T. Alain mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs Science 328 2010 1172 1176
24. A.Y. Choo, S.O. Yoon, S.G. Kim, P.P. Roux, J. Blenis Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation Proc Natl Acad Sci U S A 105 2008 17414 17419
25. M. Fosbrink, F. Niculescu, V. Rus, M.L. Shin, H. Rus C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1 J Biol Chem 281 2006 19009 19018
26. R.J. Dowling, M. Zakikhani, I.G. Fantus, M. Pollak, N. Sonenberg Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 67 2007 10804 10812
27. I. Ben Sahra, K. Laurent, A. Loubat The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 27 2008 3576 3586
28. Y. Zhuang, W.K. Miskimins Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1 J Mol Signal 3 2008 18
29. A. Vazquez-Martin, C. Oliveras-Ferraros, J.A. Menendez The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells Cell Cycle 8 2009 88 96
30. O. Dormond, J.C. Madsen, D.M. Briscoe The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells J Biol Chem 282 2007 23679 23686
31. B. Fisslthaler, I. Fleming Activation and signaling by the AMP-activated protein kinase in endothelial cells Circ Res 105 2009 114 127
32. D. Guo, S. Chien, J.Y. Shyy Regulation of endothelial cell cycle by laminar versus oscillatory flow: distinct modes of interactions of AMP-activated protein kinase and Akt pathways Circ Res 100 2007 564 571
33. K.E. O'Reilly, F. Rojo, Q.B. She mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508
34. D. Zhong, X. Liu, F.R. Khuri, S.Y. Sun, P.M. Vertino, W. Zhou LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins Cancer Res 68 2008 7270 7277
35. X. Wang, P. Yue, Y.A. Kim, H. Fu, F.R. Khuri, S.Y. Sun Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation Cancer Res 68 2008 7409 7418
36. K.J. Mather, S. Verma, T.J. Anderson Improved endothelial function with metformin in type 2 diabetes mellitus J Am Coll Cardiol 37 2001 1344 1350